Panel Discussion: Review of the Last 12 Months of Development of Alpha Emitting Therapies
Time: 5:30 pm
day: Day Two
Details:
- Discuss how Lutathera has changed the game for RLT developers and what it has taught us about RLT’s place on the wider oncology field
- Explore what key learnings have been uncovered by VISION trial and other recent analyses of alphaemitters’ clinical applications